CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.
Ramucirumab and Paclitaxel +/- Zanidatamab in HER2 Overexpressing Advanced Gastroesophageal Adenocarcinoma
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL
PROMOTE-HN PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
De-escalation of Breast Radiation (DEBRA) for Conservative Treatment of Stage 1, HR+, HER2 -, RS <18 Breast Cancer
COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
Archived Bulletins
Under the supervision of the Compliance Group Team Leader, the Cancer Research Monitor/Auditor will conduct quality control and assurance activities for clinical trials in North America, providing support to both the monitoring and audit programs of the Canadian Cancer Trials Group, as required.
CRC8 A Randomized Phase III Study of Nivolumab after Combined Modality Therapy (CMT) in High-Risk Anal Cancer has closed to accrual after successfully reaching, and surpassing the target accrual.
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
The SC24 randomized phase II/III study comparing stereotactic body radiotherapy(SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases has been permanently closed following primary publication.
MAC23 study, "RT CHARM:Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction" was closed to accrual after reaching its accrual target. This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
CCTG is seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required. Interest in investigational new drug trials, thoracic, gynecological, or genitourinary cancers is desirable but not required. As one of our Senior Investigators you will be co-principal investigator of individual trials, and leader within the CCTG program and the CCTG scientific committees. Senior Investigators also have Faculty appointments at Queen’s University.
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.
